Breaking News

FDA Approves Dendreon Expansion

Dendreon Corp. received approval from the FDA for the expansion of its NJ manufacturing facility, allowing the company to significantly increase the availability of Provenge.

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Dendreon Corp. received approval from the FDA for the expansion of its NJ manufacturing facility, allowing the company to significantly increase the availability of Provenge (sipuleucel-T), a treatment for metastatic castrate resistant (hormone refractory) prostate cancer. The FDA approved Provenge last April. At that time Dendreon had 12 workstations at its NJ facility to supply the drug. The FDA has approved 36 additional workstations, bringing the total workstation count to 48. With the a...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters